Quatrx Pharmaceuticals announced detailed primary endpoint results from a pivotal look 3 hydropathic dry run of Ophena(TM) (ospemifene tablets) to explore postmenopausal women with symptoms of vulvovaginal atrophy, a common discipline synergetic with menopause. . The study successfully met all four co-primary endpoints.